In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma

British Journal of Cancer

Volumn 102, Issue 1, 2010, Pages 134-143

  El Sahwi, K ^a   Bellone, S ^a   Cocco, E ^a   Cargnelutti, M ^a   Casagrande, F ^a   Bellone, M ^a   Abu Khalaf, M ^a   Buza, N ^a   Tavassoli, F A ^a   Hui, P ^a   Silasi, D A ^a   Azodi, M ^a   Schwartz, P E ^a   Rutherford, T J ^a   Pecorelli, S ^b   Santin, A D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Endometrial carcinoma; Pertuzumab; Trastuzumab; Uterine serous papillary cancer

Indexed keywords

CHROMIUM; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 2; PERTUZUMAB; RITUXIMAB; TRASTUZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; C ERBB2 GENE; CANCER CELL CULTURE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG POTENTIATION; ENDOMETRIUM CARCINOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UTERUS SEROUS PAPILLARY ADENOCARCINOMA;

ADENOCARCINOMA, PAPILLARY; AGED; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL LINE, TUMOR; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; DIMERIZATION; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTES; MIDDLE AGED; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; UTERINE NEOPLASMS;

EID: 74249095141     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605448     Document Type: Article

References (34)

1. Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, Sliwkowski MX (2006) Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 55: 717-727
2. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX (2002) Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2: 127-137
3. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G (2005) Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor in patients with advanced cancer. J Clin Oncol 23: 2534-2543
4. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V., Bertheau P, Garnier J, Jeannin JF, Coudert B (2006) Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94: 259-267
5. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, McKenzie S, Yin S, Bast Jr RC (1990) Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087-4091
6. Berchuck A, Rodriguez G, Kinney RB, Soper JT, Dodge RK, Clarke-Pearson DL, Bast Jr RC (1991) Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 164: 15-21
7. Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, Baselga J, Caligiuri MA (2001) Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J immunol 31: 3016-3025
8. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6: 443-446
9. Creasman WT, Odicino F, Maisonneuve P, Beller U, Benedet JL, Heintz AP, Ngan HY, Sideri M, Pecorelli S (2001) Carcinoma of the corpus uteri. J Epidemiol Biostat 6: 47-86
10. Diaz-Montes TP, Ji H, Sehdev AE, Zahurak ML, Kurman RJ, Armstrong DK, Bristow RE (2006) Clinical significance of Her-2/neu overexpression in uterine serous carcinoma. Gynecol Oncol 100: 139-144
11. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C, Gibelli N, Oliviero B, Ballardini B, Da Prada G, Zambelli A, Costa A (2004) Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10: 5650-5655
12. Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L (2006) Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 24: 4324-4332
13. Grushko TA, Filiaci VL, Mundt AJ, Ridderstrale K, Olopade OI, Fleming GF (2008) Gynecologic Oncology Group. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 108: 3-9
14. Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS, Podratz KC (1992) HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 47: 179-185
15. Jackson JG, St. Clair P, Sliwkowski MX, Brattain MG (2004) Blockade of epidermal growth factor-or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res 64: 2601-2609
16. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer Statistics 2008. CA Cancer J Clin 58: 71-96
17. Mullen P, Cameron DA, Hasmann M, Smyth JF, Langdon SP (2007) Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. Mol Cancer Ther 6: 93-100
18. Nahta R, Hung M, Esteva FJ (2004) The HER-2 targeting antibody trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64: 2343-2346
19. Repka T, Chiorean EG, Gay J, Herwig KE, Kohl VK, Yee D, Miller JS (2003) Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. Clin Cancer Res 9: 2440-2446
20. Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ, Parham GP (2002) Over-expression of HER-2/Neu in uterine serous papillary cancer. Clin Cancer Res 8: 1271-1279
21. Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S (2008) Tras-tuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynecol Obstet 102: 128-131
22. Santin AD, Bellone S, Van Stedum S, Bushen W, De Las Casas LE, Korourian S, Tian E, Roman JJ, Burnett A, Pecorelli S (2005a) Determination of HER2/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol Oncol 98: 24-30
23. Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S (2005b) Amplification of c-erbB-2 oncogene. A major prognostic indicator in uterine serous papillary carcinoma. Cancer 104: 1391-1397
24. Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Zhan D, Pecorelli S, Parham GP, Cannon MJ (1999) Induction of human papillo-mavirus-specific CD4+ and CD8+ lymphocytes by E7 pulsed autologous dendritic cells in patients with HPV16 and 18 positive cervical cancer. J Virol 73: 5402-5410
25. Santin AD, Rose GS, Hiserodt JC, Fruehauf J, Eck LM, Garcia RI, Schranz V, Disaia PJ, Pecorelli S, Granger GA (1996) Effects of tumor necrosis factor-a plus interferon-g combined with high dose g irradiation on the expression of major histocompatibility complex molecules and intercellular adhesion molecule-1 in human ovarian cancers. Int J Cancer 65: 688-694
26. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene. Science 235: 177-182
27. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 344: 783-792
28. Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH (2004) Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 22: 3126-3132
29. Sorosky J (2008) Endometrial cancer. Obstet Gynecol 111: 436-447
30. Takai N, Jain A, Kawamata N, Popoviciu LM, Said JW, Whittaker S, Miyakawa I, Agus DB, Koeffler HP (2005) 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer 104: 2701-2708
31. Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G, Silva LS, Villani L, Tagliabue E, Menard S, Costa A, Fagnoni FF (2007) Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 67: 11991-11999
32. Villella JA, Cohen S, Smith DH, Hibshoosh H, Hershman D (2006) HER-2/Neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int J Gynecol Cancer 16: 1897-1902
33. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726
34. Yarden Y, Sliwkowski MX (2001) Untangling the erbB signaling network. Nat Rev Mol Cell Biol 2: 127-137